In support of PIM1 as a prognostic biomarker, we found its high expression to be significantly associated with worse overall survival (p < 0.001, Bonferroni-corrected, Log-rank test) in an independent cohort of NB patients (n = 498) (Supplementary Fig. 5a)28. Here, PIM1 is linked to neuroblastoma.